Cargando…
SUN-413 Dual Endocrinopathies Following Single Dose of Pembrolizumab Therapy
Introduction: Immune related endocrine adverse effects (IReAs) caused by checkpoint inhibitors (CI) used in the treatment of advanced cancers are rare and often under recognized, but they can be potentially life-threatening. Case: A 69 y/o male with stage 4 metastatic colon cancer was evaluated 10 d...
Autores principales: | Parikh, Tanvi, Sharma, Meeta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552853/ http://dx.doi.org/10.1210/js.2019-SUN-413 |
Ejemplares similares
-
SUN-412 A Unique Case of Isolated ACTH Deficiency Caused by Pembrolizumab
por: Erenler, Feyza, et al.
Publicado: (2019) -
FRI344 Is It Possible To Have Two Endocrinopathies From Checkpoint Inhibitor Therapy At The Same Time?
por: Davis, Adam N, et al.
Publicado: (2023) -
MON-413 First Reported Case of Combined High-Dose Mifepristone Therapy and Oral Contraceptive in Inducing Reversible Cholestatic Hepatitis in a Patient with Cushing Disease
por: Youssef, Nancy, et al.
Publicado: (2019) -
SUN-276 Pembrolizumab-Induced Secondary Adrenal Insufficiency Presenting as Severe Hyponatremia in an 80-Year-Old Male
por: Kawaji, Leslie Daphne R, et al.
Publicado: (2020) -
SAT-413 Examining Alterations to Arcuate Nucleus NPY Neurons and Their Neural Projections in a Mouse Model of PCOS
por: Marshall, Christopher, et al.
Publicado: (2019)